Vacquinol-1 is an MKK4 activator, which rapidly and selectively induces glioma cell death.
|Solubility (25°C)||DMSO 70 mg/mL|
Powder -20°C 3 years ; 4°C 2 years
In solvent -80°C 6 months ; -20°C 1 month
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Lars G J Hammarstrm, et al. The Oncolytic Efficacy and in Vivo Pharmacokinetics of [2-(4-Chlorophenyl)quinolin-4-yl](piperidine-2-yl)methanol (Vacquinol-1) Are Governed by Distinct Stereochemical Features
|Related JNK Products|
JNK-1-IN-1 is a JNK-1 inhibitor.
JNK2-IN-1 is a JNK2 inhibitor (Kds: 79.2 μM).
JNK-1-IN-2 is a JNK-1 inhibitor (IC50: 33.5 nM).
JNK3 inhibitor-6 is a selective JNK3 Inhibitor (IC50=78 nM).
JNK3 inhibitor-7 is a potent, orally active and cross the blood-brain barrier JNK3 inhibitor with IC50 values of 53, 973, 1039 nM for JNK3, JNK2, JNK1, respectively.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.